MichaelEvanLeesMD

PubMed

• 33 citations
  Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective
  A. Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis M. Kwong, Michael Lees> ;Pharmacoeconomics. 2012 Oct 11
• 15 citations
  Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective
  Heather McDonald, Alex Diamantopoulos, Philip S. Wells, Michael Lees, Kerstin Folkerts, Fiona Forster, Jaithri Ananthapavan> ;Journal of Medical Economics. 2012 Apr 12
• 13 citations
  Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective
  A. Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis M. Kwong, Michael Lees> ;Journal of Medical Economics. 2011 Nov 13
• 22 citations
  Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
  Lars Ryttberg, A. Diamantopoulos, Fiona Forster, Michael Lees, Anina Fraschke, Ingela Bjorholt> ;Expert Review of Pharmacoeconomics & Outcomes Research. 2011 Oct 1
• 8 citations
  Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
  Richard J. Friedman, Nishan Sengupta, Michael Lees> ;Expert Review of Pharmacoeconomics & Outcomes Research. 2011 Jun 1
• 9 citations
  An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
  C. LeReun, P. S. Wells, Alex Diamantopoulos, Farhat Rasul, Michael Lees, Nishan Sengupta> ;Journal of Medical Economics. 2011 Mar 24
• 113 citations
  Economic Burden of Venous Thromboembolism: A Systematic Review
  Andras Ruppert, Thomas Steinle, Michael Lees> ;Journal of Medical Economics. 2011 Jan 17
• 33 citations
  Clinical burden of venous thromboembolism
  Andras Ruppert, Michael Lees, Thomas Steinle> ;Current Medical Research and Opinion. 2010 Sep 15
• 45 citations
  Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
  Alexander Diamantopoulos, Michael Lees, Philip S. Wells, Fiona Forster, Jaithri Ananthapavan, Heather McDonald> ;Thrombosis and Haemostasis. 2010 Aug 30
• 41 citations
  Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
  Steven Crowley, David Tognarini, Paul V. Desmond, Michael Lees, Gauri Saal> ;Journal of Gastroenterology and Hepatology. 2002 Feb 1
• 36 citations
  Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B.
  Steven Crowley, David Tognarini, Paul V. Desmond, Michael Lees> ;Pharmacoeconomics. 2000 May 1
• Join now to see all